Effectiveness of Local Treatment in Patients with Chronic Venous Disease

Kalinin R.E.; Suchkov I.A.; Kamaev A.A.

doi:https://doi.org/10.17116/flebo202115041290

Close metadata

Recommended articles:

Objective Monitoring of Compliance with Compression Treatment in Patients with Chronic Venous Disease is Better than Self-Reported Using Patient’s Diary. Journal of Venous Disorders. 2025;(2):113-119

Clinical Decisions in the Absence of Evidence: Expert’s Panel Recommendations for the Management of Chronic Venous Disease and Superficial Thrombophlebitis. Journal of Venous Disorders. 2025;(2):126-140

Onset, Time Course and Duration of Venoactive Drugs Effect on Venous Symptoms in Patients with Chronic Venous Disease. Journal of Venous Disorders. 2025;(3):206-215

Predictors of Venous Symptoms Improvement in Chronic Venous Disease Patients on Compression Therapy. Journal of Venous Disorders. 2025;(4):250-256

A Topical Agent Based on Recombinant Human Epidermal Growth Factor and Silver Sulfadiazine Accelerates the Healing of Venous (Chronic) Ulcers: A Prospective Comparative Non-Randomized Study ESKIZ. Journal of Venous Disorders. 2025;(4):284-294

Diosmin and Other Venoactive Drugs: Mechanisms of Action, Current and Future Indications for Use. Journal of Venous Disorders. 2025;(4):307-314

Groin Soft Tissue Leiomyosarcoma or Femoral Vein Leiomyosarcoma?. Journal of Venous Disorders. 2025;(4):316-319

Phage therapy analysis of effectiveness in comorbid patients with wounds and surgical infections of various etiology based on the results of a comparative clinical study. Pirogov Russian Journal of Surgery. 2025;(3):124-138

Effectiveness of local treatment of venous trophic ulcers in gerontological patients. Pirogov Russian Journal of Surgery. 2025;(8):45-54

Abstract:

Chronic venous disease is the most common vascular pathology of the lower extremities. There are two main therapeutic approaches for these patients (compression hosiery and drug therapy). Patient adherence to treatment is important. Patients often experience various difficulties with daily use of compression hosiery that results poor compliance. A combined approach to local and systemic treatment is required to influence all aspects of pathogenesis and achieve physician and patient satisfaction with treatment. Venoactive drugs have a systemic effect on pathogenesis of chronic venous disease. They improve the quality of life of patients and slow down progression of disease. High efficiency of micronized purified flavonoid fraction for chronic venous diseases was confirmed in international trials. Despite the widespread distribution of local medicines and their popularity among patients, many physicians associate their effectiveness with massage and cooling effect and doubt bioavailability. In this regard, topical agents containing essential phospholipids forming liposomes are of particular interest. These agents are characterized by higher penetration into the deeper layers of skin and better effectiveness. This review is devoted to the issues of prescribing the local medicines based on heparin, escin and essential phospholipids for relief of venous-specific symptoms in patients with chronic venous diseases. We analyzed the efficacy and safety of local phlebotropic drugs and their use after invasive treatment. An integrated therapeutic approach to chronic venous disease was finally proposed.

Keywords:

chronic venous disease

local treatment

topical agents

essential phospholipids

Authors:

Kalinin R.E.

Ryazan State Medical University

ORCID: 0000-0002-0817-9573

Suchkov I.A.

Ryazan State Medical University

SPIN RSCI: 6473-8662
Scopus AuthorID: 56001271800
ResearcherID: M-1180-2016
ORCID: 0000-0002-1292-5452

Kamaev A.A.

Ryazan State Medical University

ORCID: 0000-0002-3979-1271

Received:

24.09.2021

Accepted:

10.10.2021

Close metadata

References:

Robertson L, Evans C, Fowkes FGR. Epidemiology of chronic venous disease. Phlebol J Venous Dis. 2008;23(3):103-111. https://doi.org/10.1258/phleb.2007.007061
Savelyev VS, Kirienko AI, Zolotukhin IA, Seliverstov EI. Prospective observational study SPECTRUM: register of patients with chronic venous diseases. Flebologiya. 2012;6(1):4-9. (In Russ.).
Bergan J. Molecular Mechanisms in Chronic Venous Insufficiency. Ann Vasc Surg. 2007;21(3):260-266. https://doi.org/10.1016/j.avsg.2007.03.011
Kalinin RE, Suchkov IA, Pshennikov AS, Rudakova IN, Isakov SA. Uroven’ oksida azota pri posttromboticheskom sindrome. Rossijskij mediko-biologicheskij vestnik im. akad. I.P. Pavlova. 2016;24(2):79-85. (In Russ.). https://doi.org/10.17816/PAVLOVJ2016279-85
Lim CS, Davies AH. Pathogenesis of primary varicose veins. Br J Surg. 2009;96(11):1231-1242. https://doi.org/10.1002/bjs.6798
Pocock ES, Alsaigh T, Mazor R, Schmid-Schönbein GW. Cellular and molecular basis of Venous insufficiency. Vasc Cell. 2014;6(1):24. https://doi.org/10.1186/s13221-014-0024-5
Kalinin RE, Suchkov IA, Pshennikov AS, Kamaev AA. Vliyanie urovnya magniya na kontsentratsiyu matriksnykh metalloproteinaz u patsientov s varikoznoj bolezn’yu. Flebologiya. 2016;10(4):171. (In Russ.). https://doi.org/10.17116/flebo2016104171-175
Kalinin RE, Suchkov IA, Pshennikov AS, Kamaev AA, Isakov SA, Ryabkov AN. Application of Magnesium Drugs and Their Influence on the Indicators of Connective Tissue Dysplasia in Patients with Varicose Veins. Novosti Khirurgii. 2018;26(1):51-59. https://doi.org/10.18484/2305-0047.2018.1.51
Shanaev IN. Sovremennye teorii patogeneza troficheskikh yazv venoznoj etiologii. Nauka molodykh (Eruditio Juvenium). 2019;7(4):600-611. (In Russ.). https://doi.org/10.23888/HMJ201974600-611
Stoyko YuM, Kirienko AI, Zatevakhin II, Pokrovsky AV, Karpenko AA, Zolotukhin IA, Sapelkin SV, Ilyukhin EA, Gavrilov SG, Porembskaya OYa, Borsuk DA, Seliverstov EI, Alukhanyan OA, Andriyashkin AV, Andriyashkin VV, Barinov VE, Belentsov SM, Bogdanets LI, Bredikhin RA, Bukina OV, Burleva EP, Vakhitov MSh, Vinogradov LA, Volkov AYu, Golovanova OV, Guzhkov ON, Ivanov EV, Katelnitskaya OV, Katorkin SE, Kletskin AE, Koshevoy AP, Krylov AYu, Kudykin MN, Kuzovlev SP, Laberko LA, Larin SI, Lishov DE, Lobastov KV, Mazayshvili KV, Markin SM, Parikov MA, Pelevin AV, Potapov MP, Pryadko SI, Rapovka VG, Sabelnikov VV, Slavin DA, Sokolov AL, Soldatsky EYu, Sonkin IN, Starodubtsev VN, Subbotin YuG, Suchkov IA, Sushkov SA, Tolstikhin VYu, Fokin AA, Khitariyan AG, Khodkevich MB, Khorev NG, Tsukanov YuT, Chabbarov RG, Chernookov AN, Chechetka DYu, Shevela AI, Shimanko AI, Shonov OA, Yashkin MN, Bogachev VYu, Bubnova NA, Dibirov MD, Zhukov BN, Kalinin RE, Katelnitsky II, Plechev VV, Shaydakov EV, Shulutko AM. Diagnostics and Treatment of Chronic Venous Disease: Guidelines of Russian Phlebological Association. Flebologiya. 2018;3:146-240. (In Russ.). https://doi.org/10.17116/flebo20187031146
Perrin M, Eklof B, Van Rij A, Labropoulos N, Vasquez M, Nicolaides A, Blattler W, Bouhassira D, Bouskela E, Carpentier P. Venous symptoms: the SYM Vein Consensus statement developed under the auspices of the European Venous Forum. International angiology: a journal of the International Union of Angiology. 2016;35(4):374.
Carpentier PH, Poulain C, Fabry R, Chleir F, Guias B, Bettarel-Binon C. Ascribing leg symptoms to chronic venous disorders: The construction of a diagnostic score. J Vasc Surg. 2007;46(5):991-996. https://doi.org/10.1016/j.jvs.2007.06.044
Kirienko AI, Zolotukhin IA, Yumin SM, Seliverstov EI. Effektivnost’ spetsializirovannoj flebologicheskoj pomoshchi v Rossii: rezul’taty prospektivnogo observatsionnogo issledovaniya SPEKTR. Flebologiya. 2015;9(2):4. https://doi.org/10.17116/flebo2015924-11
Baranski K, Chudek J. Factors affecting patients’ self-management in chronic venous disorders: a single-center study. Patient Prefer Adherence. 2016;10:1623-1629. https://doi.org/10.2147/PPA.S110773
Chowdhury MMU. Dermatological pharmacology: topical agents. Medicine (Baltimore). 2013;41(6):327-329. https://doi.org/10.1016/j.mpmed.2013.04.012
Lobastov KV. Impact of microcirculatory disorders on the symptoms of chronic venous disease and their pharmacological correction. Flebologiya. 2020;14(1):30-39. (In Russ.). https://doi.org/10.17116/flebo20201401130
Thong H-Y, Zhai H, Maibach HI. Percutaneous penetration enhancers: An overview. Skin Pharmacol Physiol. 2007;20(6):272-282. https://doi.org/10.1159/000107575
Savelyeva MI, Sychev DA. Potential of the Transdermal Drug Delivery Systems for the Topical Treatment of Chronic Venous Diseases. Flebologiya. 2018;12(1):40-49. (In Russ.). https://doi.org/10.17116/flebo201812140-49
Sirtori CR. Aescin: Pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44(3):183-193. https://doi.org/10.1006/phrs.2001.0847
Diehm C, Trampisch HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet (London, England). 1996; 347(8997):292-294. https://doi.org/10.1016/s0140-6736(96)90467-5
Zhao S-Q, Xu S-Q, Cheng J, Cao XL, Zhang Y, Zhou WP, Huang YJ, Wang J, Hu XM. Anti-inflammatory effect of external use of escin on cutaneous inflammation: possible involvement of glucocorticoids receptor. Chin J Nat Med. 2018;16(2):105-112. https://doi.org/10.1016/S1875-5364(18)30036-0
Montopoli M, Froldi G, Comelli MC, Prosdocimi M, Caparrotta L. Aescin protection of human vascular endothelial cells exposed to cobalt chloride mimicked hypoxia and inflammatory stimuli. Planta Med. 2007; 73(3):285-288. https://doi.org/10.1055/s-2007-967118
Domanski D, Zegrocka-Stendel O, Perzanowska A, Dutkiewicz M, Kowalewska M, Grabowska I, Maciejko D, Fogtman A, Dadlez M, Koziak K. Molecular Mechanism for Cellular Response to β-Escin and Its Therapeutic Implications. PLoS One. 2016;11(10):e0164365. https://doi.org/10.1371/journal.pone.0164365
Lang W. Percutaneous absorption of 3H-aescin in mice and rats. Arzneimittelforschung. 1974;24(1):71-76.
Lang W. Studies on the percutaneous absorption of 3H-aescin in pigs. Res Exp Med (Berl). 1977;169(3):175-187. https://doi.org/10.1007/BF01852057
Gallelli L. Escin: A review of its anti-edematous, anti-inflammatory, and venotonic properties. Drug Des Devel Ther. 2019;13:3425-3437. https://doi.org/10.2147/DDDT.S207720
Lehman CM, Frank EL. Laboratory Monitoring of Heparin Therapy: Partial Thromboplastin Time or Anti-Xa Assay? Lab Med. 2009;40(1):47-51. https://doi.org/10.1309/LM9NJGW2ZIOLPHY6
Vecchio C, Frisinghelli A. Topically applied heparins for the treatment of vascular disorders: a comprehensive review. Clin Drug Investig. 2008;28(10): 603-614. https://doi.org/10.2165/00044011-200828100-00001
Villardell M, Sabat D, Arnaiz JA, Bleda MJ, Castel JM, Laporte JR, Vallvé C. Topical heparin for the treatment of acute superficial phlebitis secondary to indwelling intravenous catheter. A double-blind, randomized, placebo-controlled trial. Eur J Clin Pharmacol. 1999;54(12):917-921. https://doi.org/10.1007/s002280050575
Lever R, Page CP. Non-anticoagulant Effects of Heparin: An Overview. Handb Exp Pharmacol. 2012;(207):281-305. https://doi.org/10.1007/978-3-642-23056-1_12
Bazzoni G, Nuñez AB, Mascellani G, Bianchini P, Dejana E, Del Maschio A. Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med. 1993;121(2):268-275.
Silvestro L, Viano I, Macario M, Colangelo D, Montrucchio G, Panico S, Fantozzi R. Effects of Heparin and Its Desulfated Derivatives on Leukocyte-Endothelial Adhesion. Semin Thromb Hemost. 1994;20(03):254-258. https://doi.org/10.1055/s-2007-1001910
Smailbegovic A, Lever R, Page CP. The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells. Br J Pharmacol. 2001;134(4):827-836. https://doi.org/10.1038/sj.bjp.0704321
Lever R, Smailbegovic A, Page CP. Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity. Eur J Pharmacol. 2010;630(1):137-144. https://doi.org/10.1016/j.ejphar.2009.12.015
Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998;101(4):877-889. https://doi.org/10.1172/JCI1509
Skinner MP, Lucas CM, Burns GF, Chesterman CN, Berndt MC. GMP-140 binding to neutrophils is inhibited by sulfated glycans. J Biol Chem. 1991; 266(9):5371-5374. https://doi.org/10.1016/S0021-9258(19)67603-9
Watt SM, Williamson J, Genevier H, Fawcett J, Simmons DL, Hatzfeld A, Nesbitt SA, Coombe DR. The heparin binding PECAM-1 adhesion molecule is expressed by CD34+ hematopoietic precursor cells with early myeloid and B-lymphoid cell phenotypes. Blood. 1993;82(9):2649-2663. https://doi.org/10.1182/blood.V82.9.2649.2649
Vaghasiya K, Sharma A, Kumar K, Ray E, Adlakha S, Katare OP, Hota SK, Verma RK. Heparin-Encapsulated Metered-Dose Topical “Nano-Spray Gel” Liposomal Formulation Ensures Rapid On-Site Management of Frostbite Injury by Inflammatory Cytokines Scavenging. ACS Biomater Sci Eng. 2019; 5(12):6617-6631. https://doi.org/10.1021/acsbiomaterials.9b01486
Porembskaya OYa. Topicheskie sredstva dlya lecheniya khronicheskikh zabolevanij ven. Sostav kak osnova effektivnosti. Flebologiya. 2020;14(4):322-327. (In Russ.). https://doi.org/10.17116/flebo202014041322
Incandela L, Belcaro G, Cesarone MR, De Sanctis MT, Griffin M. Microangiopathy and Venous Ulceration: Topical Treatment with Essaven Gel. Angiology. 2001;52(3 Suppl):S17-S21. https://doi.org/10.1177/0003319701052003S05
Belcaro G, Cesarone MR, Dugall M. Microcirculatory Efficacy of Topical Treatment with Aescin + Essential Phospholipids Gel in Venous Insufficiency and Hypertension: New Clinical Observations. Angiology. 2004;55 (6 Suppl):1-5. https://doi.org/10.1177/000331970405500601
Ruffini I, Belcaro G, Cesarone MR, Dugall M. Efficacy of Topical Treatment with Aescin + Essential Phospholipids Gel in Venous Insufficiency and Hypertension. Angiology. 2004;55(6 Suppl):19-21. https://doi.org/10.1177/000331970405500605
Cesarone MR, Belcaro G, Ippolito E, Ricci A, Ruffini M, Dugall M. Microcirculatory Efficacy of Topical Treatment with Aescin + Essential Phospholipids Gel on Transcutaneous PO2 in Venous Insufficiency. Angiology. 2004;55(6 Suppl):7-10. https://doi.org/10.1177/000331970405500602
Ricci A, Ruffini I, Cesarone MR, Cornelli U, Corsi M, Belcaro G, Ippolito E, Dugall M. Variations in Plasma Free Radicals with Topical Aescin + Essential Phospholipids Gel in Venous Hypertension: New Clinical Data. Angiology. 2004;55(6 Suppl):11-14. https://doi.org/10.1177/000331970405500603
Bogachev VYu, Boldin BV, Turkin PYu. Modern therapy of chronic venous disorders of the lower limbs: transdermal phlebotropic medications in focus. RMZh. 2018;6:61-65 (In Russ.).
Bogachev VYu, Boldin BV, Turkin PYu, Lobanov VN. Local drugs in treat- ing and decreasing the incidence of adverse reactions after sclerotherapy of telangiectasia. Angiologiya i sosudistaya khirurgiya. 2019;25(4):102-106. (In Russ.). https://doi.org/10.33529/angio2019405